Regulatory Context for Patent Law
Patent law in the United States operates within a dense federal regulatory framework anchored by Title 35 of the U.S. Code, administered primarily by the United States Patent and Trademark Office (USPTO). The scope of that framework determines what inventions can be protected, how long protection lasts, and what remedies are available when rights are infringed. Understanding the agencies, statutes, and procedural instruments involved is foundational to any engagement with the patent application process, patent prosecution, or post-grant dispute resolution.
Enforcement and review paths
Patent rights are enforced through two parallel systems: federal district court litigation and administrative proceedings before the USPTO's Patent Trial and Appeal Board (PTAB).
Federal district courts have exclusive jurisdiction over patent infringement claims under 28 U.S.C. § 1338. Appeals from those courts proceed to the United States Court of Appeals for the Federal Circuit, which has exclusive appellate jurisdiction over patent matters. The Federal Circuit's decisions establish binding precedent on claim construction, patent eligibility under 35 U.S.C. § 101, and damages calculations.
PTAB provides three administrative review mechanisms:
- Inter Partes Review (IPR) — Challenges patent validity on novelty and non-obviousness grounds (§§ 102–103), based on prior art consisting of patents or printed publications. Petitions must be filed within 1 year of service of a complaint alleging infringement (35 U.S.C. § 315(b)).
- Post-Grant Review (PGR) — Permits challenges on any ground of invalidity, but petitions must be filed within 9 months of the patent's grant or reissuance.
- Ex Parte Reexamination — Allows any party, including the patent owner, to request USPTO examination of one or more claims based on prior art patents or printed publications.
Appeals from USPTO rejections during prosecution first proceed to PTAB, then to the Federal Circuit or to the U.S. District Court for the Eastern District of Virginia under 35 U.S.C. § 145.
Primary regulatory instruments
The core statutory authority for U.S. patent law is Title 35 of the United States Code, enacted and periodically revised by Congress. The most significant modern revision is the Leahy-Smith America Invents Act (AIA) of 2011 (Pub. L. 112-29), which converted the United States from a first-to-invent to a first-inventor-to-file system, effective March 16, 2013.
Implementing regulations appear in Title 37 of the Code of Federal Regulations (C.F.R.), Parts 1–199, promulgated by the USPTO. These regulations govern procedural requirements including filing deadlines, fee structures, oath and declaration requirements, and examination standards. The USPTO's Manual of Patent Examining Procedure (MPEP) — publicly available at mpep.uspto.gov — provides examiners and practitioners with detailed guidance on every aspect of examination, from patent claims drafting to patent specification requirements.
For pharmaceutical and biotechnology inventions, regulatory interaction extends beyond the USPTO to the Food and Drug Administration (FDA). The Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. 98-417) created the Orange Book listing system and established a framework linking FDA drug approval to pharmaceutical patent law protection, including patent term extensions of up to 5 years to compensate for regulatory review time (35 U.S.C. § 156).
International regulatory instruments include the Paris Convention for the Protection of Industrial Property (administered by WIPO) and the Patent Cooperation Treaty (PCT), which allows a single international application to establish priority in more than 150 contracting states. The Patent Cooperation Treaty framework is detailed in the PCT Applicant's Guide published by WIPO.
Compliance obligations
Entities engaging with the patent system carry specific affirmative compliance duties. Failure to meet them can result in loss of rights, unenforceability, or enhanced liability.
Duty of candor — Inventors, applicants, and their representatives owe a duty of candor and good faith to the USPTO under 37 C.F.R. § 1.56. Withholding known material prior art can render a patent unenforceable for inequitable conduct, a defense firmly established in Federal Circuit precedent.
Inventorship accuracy — A patent must name all true inventors and no non-inventors. Misjoinder or non-joinder of inventors, if not corrected, can invalidate a patent (35 U.S.C. § 256). Joint inventorship rules require that each named inventor contribute to the conception of at least one claim.
Maintenance fees — Utility patents require maintenance fees paid to the USPTO at 3.5, 7.5, and 11.5 years post-grant. As of the USPTO's current fee schedule (USPTO Fee Schedule), failure to pay within the 6-month grace period results in expiration, though late reinstatement is available if the delay was unintentional.
Patent marking requirements — Patentees who commercially practice their invention must mark articles with the patent number or a virtual marking URL to recover damages for pre-lawsuit infringement (35 U.S.C. § 287).
Government contractor obligations — Under the Bayh-Dole Act (35 U.S.C. §§ 200–212), recipients of federal funding who make patentable inventions must disclose those inventions to the funding agency within 2 months of the inventor's report. Failure to disclose can transfer ownership rights to the federal government.
The broader dimensions of these obligations are mapped across key dimensions and scopes of patent law and throughout the Patent Law Authority site index.
Exemptions and carve-outs
Several statutory and judicially created exemptions limit the scope of patent rights, protecting specific actors and activities from infringement liability.
Research exemption (experimental use) — A narrow common-law exemption exists for purely experimental use having no commercial purpose, established in Madey v. Duke University (Fed. Cir. 2002). The exemption is extremely limited and does not extend to university research that advances institutional commercial interests.
Hatch-Waxman safe harbor — Under 35 U.S.C. § 271(e)(1), it is not infringement to make, use, or sell a patented invention solely for uses reasonably related to FDA approval submissions. This provision enables generic drug manufacturers to conduct bioequivalence studies before patent expiration.
Patent exhaustion doctrine — Once a patentee makes an authorized sale of a patented article, the patent rights in that specific article are exhausted. The Supreme Court's decision in Impression Products, Inc. v. Lexmark International, Inc. (580 U.S. 520, 2017) confirmed that exhaustion applies to authorized foreign sales as well as domestic ones.
Prior commercial use defense — Under the AIA, a party who commercially used a process, machine, or composition of matter in the United States at least 1 year before the effective filing date of the asserted patent may assert that use as a defense to infringement (35 U.S.C. § 273).
Government use — Under 28 U.S.C. § 1498, the federal government may use any patented invention without license, but the patent owner retains the right to seek reasonable compensation through a claim filed in the U.S. Court of Federal Claims.